# Cabergoline Versus GnRH Antagonist Rescue and Cabergoline in the Prevention of Ovarian Hyperstimulation Syndrome

> **NCT02461875** · PHASE2 · UNKNOWN · sponsor: **Aljazeera Hospital** · enrollment: 236 (estimated)

## Conditions studied

- OHSS

## Interventions

- **DRUG:** Cabergoline
- **DRUG:** GnRH antagonist rescue & cabergoline

## Key facts

- **NCT ID:** NCT02461875
- **Lead sponsor:** Aljazeera Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-05
- **Primary completion:** 2015-11
- **Final completion:** 2015-12
- **Target enrollment:** 236 (ESTIMATED)
- **Last updated:** 2015-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02461875

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02461875, "Cabergoline Versus GnRH Antagonist Rescue and Cabergoline in the Prevention of Ovarian Hyperstimulation Syndrome". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02461875. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*